摘要
目的:观察重组人血小板生成素(recombinanthuman-thrombopoietin,rhTPO)治疗肿瘤化疗所致血小板减少的有效性及安全性。方法:回顾性分析我院经化疗后血小板计数≤50×109/L的肿瘤患者87例,分为rhTPO组45例和国产组白介素11(rhIL-11)组42例。rhTPO组给予rhTPO300u/kg,皮下注射每日1次,连续使用;rhIL-11组给予rhIL-111.5mg皮下注射,每日1次,连续使用;两组在用药过程中待血小板计数恢复至≥100×109/L以上或血小板计数绝对值升高≥50×109/L时即停用。结果:rhTPO组患者血小板计数恢复至100×109/L平均使用7天,有效率86.6%;rhIL-11组患者血小板计数恢复至100×109/L平均使用11天,有效率69%,两组疗效比较有统计学差异(P<0.05)。rhTPO组和rhIL-11组因出现出血症状而采取输注血小板患者例数分别为1例和3例。结论:rhTPO对肿瘤化疗所致的血小板减少症有效率高,起效快,安全性高,值得进一步推广。
Objective：To investigate the effectiveness and safety of chemotherapy reduced thrombocytopenia with recombinant human thrombopoietin （RhTPO）. Methods：Total of 87 cases were retrospectively analysed with platelet count lower than 50 ×10^9/L and divided into two groups, RhTPO group （45 cases） and domestic interleukin （rhIL - 11 ） group （42 cases）. In RhTPO group rhTPO was given 300u/kg,hypodermic once daily,in RhIL - 11 group rhlL - 11 to 1.5 mg subcutaneous injection, once per day, for two groups in the process of platelet counts to PTL above 100 ×10^9/L or platelet counts increase 50×10^9/L. Results： rhTPO group platelet count recovered to 100 ×10^9/L in seven days,and effective rate was 86.6% ;RhIL- 11 group to 100 x 109/L in 11 days,effective rate was 69% （P 〈 0.05）. Conclusion： rhTPO for chemotherapy induced thrombocytopenia is effective and safe.
出处
《现代肿瘤医学》
CAS
2010年第5期998-1000,共3页
Journal of Modern Oncology
